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What are we covering today? 
• DM statistics 
• Screening  
• Pharmacotherapy 
 
2 
What percent of the US population 
has Diabetes Mellitus?  
A. 9% 
B. 18% 
C. 27% 
D. 36% 
E. 45% 
3 
Background 
21.0 million 
people 
Diagnosed 
8.1 million 
people 
Undiagnosed 
TOTAL 
29.1 million 
people  
 
9.3% of the 
population 
have 
diabetes 
 
http://www.cdc.gov/diabetes/pubs/statsreport14.htm   
CDC  National Diabetes Statistics Report, 2014 4 
Age-adjusted* percentage of people aged 20 years 
or older with diagnosed diabetes, by 
race/ethnicity, United States, 2010–2012 
15.9
13.2
12.8
9.0
7.6
American Indians/
Alaska Natives
Non-Hispanic blacks
Hispanics
Asian Americans
Non-Hispanic whites
*Based on the 2000 U.S. standard population.  Source: 2010–2012 National Health Interview Survey and 2012 Indian Health Service’s 
National Patient Information Reporting System. CDC  National Diabetes Statistics Report, 2014 
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Rate of new cases of type 1 and type 2 diabetes among people 
younger than 20 years, by age and race/ethnicity, 2008–2009 
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Source: SEARCH for Diabetes in Youth Study. NHW=non-Hispanic whites; NHB=non-Hispanic blacks; H=Hispanics; API=Asians/Pacific Islanders; 
AIAN=American Indians/Alaska Natives. 
*The American Indian/Alaska Native (AI/AN) youth who participated in the SEARCH study are not representative of all AI/AN youth in the United 
States. Thus, these rates cannot be generalized to all AI/AN youth nationwide. 
CDC  National Diabetes Statistics Report, 2014 
<10 years 10–19 years 
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Self Assessment 
• For every 1 % decrease in A1c, risk of 
microvascular complications decreases by 
____? 
 
A. 20% 
B. 40% 
C. 60% 
D. 80% 
Diabetes Care 2007;30(suppl 1):S4-S41 
7 
UKPDS: Glycemic Control-Effects on 
Microvascular Endpoints 
8 
Stratton IM, et al. BMJ. 2000; 321:405-412 
Chronic 
Complications 
• Heart disease  
• Stroke 
• Hypertension 
• Blindness/ 
Retinopathy 
• Nephropathy 
• Neuropathy 
• Amputations 
• Dental disease 
 CDC  National Diabetes Statistics Sheet, 2014   Image: https://www.mja.com.au/journal/2003/179/9/3-preventing-
complications-diabetes 
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Impact of Intensive Therapy for Diabetes:  
Summary of Major Clinical Trials 
Study 
Microvasc 
Initial/Long-term 
CVD 
Initial/Long-term 
Mortality 
Initial/Long-term 
UKPDS       
DCCT / EDIC*        
ACCORD    
ADVANCE    
VADT    
 
Kendall DM, Bergenstal RM.  © International Diabetes Center 2009 
UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854.  
Holman RR et al. N Engl J Med. 2008;359:1577.  DCCT Research Group. N Engl J Med 1993;329;977. 
Nathan DM et al. N Engl J Med. 2005;353:2643.  Gerstein HC et al. N Engl J Med. 2008;358:2545. 
Patel A et al. N Engl J Med 2008;358:2560.   
Duckworth W et al.  N Engl J Med 2009;360:129. (erratum: Moritz T. N Engl J Med 2009;361:1024) 10 
 At what age should we start 
screening for DM in ALL patients? 
A. 25 years old 
B. 45 years old 
C. 65 years old 
D. There is no set age, screen only if risk 
factors present 
11 
Who Should be Tested? 
Asymptomatic Adults 
• All adults  45 years  
• Of any age if overweight (BMI > 25) and one or more risk 
factors 
– Inactive 
– First degree relative with DM 
– High risk ethnic population 
– GDM or delivered baby >9 pounds 
– HTN 
– Low HDL (<35) or high triglycerides (>250) 
– PCOS 
– Previous A1c >5.7%, IGT, or IFG 
– Acanthosis nigricans 
– History of cardiovascular disease 
• Repeat every year for pre-DM otherwise every 3 years 
 
ADA. Testing for Diabetes in Asymptomatic Patients. Diabetes Care 2014;37(suppl 1):S17; Table 4 
12 
When Should Children be Tested? 
Overweight   
(Weight > 120% ideal for height or BMI >85th percentile) 
Family history 
of DM in 1st or 
2nd degree 
relative 
High risk 
ethnic group 
Signs of insulin 
resistance 
(acanthosis 
nigricans, HTN, 
dyslipidemia, 
PCOS) 
Maternal h/o 
DM during 
child's 
gestation 
Plus any TWO 
Start at 10 years old and test every 3 years  
ADA. Testing for Diabetes in Asymptomatic Patients. Diabetes Care 2014;37(suppl 1):S17; Table 4 
13 
Watch for Drug-Induced 
Hyperglycemia 
• Pentamidine 
• Glucocorticoids 
• Nicotinic acid 
• Interferon alfa 
• Hydrochlorothiazide 
• Atypical antipsychotics 
• Protease inhibitors  
14 
Image: http://diabeteshealth.com/cartoons/general/506.html 
Which is the target for the newest 
class of oral medications in glucose 
control? 
A. Sodium glucose co-transporters 
B. Sodium potassium ATPase 
C. Glucose transport by GLUT-4  
D. Octreotide-like peptides 
15 
Treatment Options-Oral 
• Biguanide 
• Sulfonylureas  
• Meglitinides  
• Thiazolidindiones 
• Alpha-glucosidase inhibitors 
• Dipeptidyl peptidase-IV (DPP-4) inhibitors  
• Selective sodium-glucose transporter-2 (SGLT-2) 
• Bile acid sequestrants and dopamine agonists 
 
Garber AJ. Et al.  Endocrine Practice. 2013; 19: 327-336 (NE 16 
FDA approved options- 
Injectable agents 
• Insulin 
• Glucagon like peptide-1 (GLP-1) agonists  
• Amylin analog 
 
 
17 
Approach to Management of Hyperglycemia 
ADA. Diabetes Care. Diabetes Care 2014;37(suppl 1):S25. Figure 1; adapted with permission from 
Ismail-Beigi F, et al. Ann Intern Med 2011;154:554-559 
18 
Pathophysiology of Diabetes 
DeFronzo RA. Diabetes. 2009; 58: 773-95 19 
Progression of Type 2 Diabetes 
Relative 
Activity 
Glucose 
Years from Diabetes Diagnosis 
–10 –5 0 5 10 15 20 25 30 
-10 -5 0 5 10 15 20 25 30 
NGT   Insulin Resistance  IGT/ IFG  Type 2 Diabetes 
 
Postprandial glucose 
Fasting glucose 
Insulin resistance —
hepatic and peripheral 
Insulin level 
Beta-cell function 
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Biguanide (metformin) 
• First line therapy 
• Lowers HbA1c 1-2 % 
• MoA-hepatic glucose production, increase insulin 
sensitivity 
• ADR 
– Common: nausea, vomiting, diarrhea (especially early)  
– Uncommon-B12 deficiency, lactic acidosis 
• Weight loss or negligible 
• Contraindications/Precautions-renal insufficiency, 
HF, contrast CT scan 
21 
Sulfonylureas (glipizide, glimepiride, 
glyburide) 
• MoA-increase insulin secretion from pancreas 
• Lowers HbA1c 1-2% 
• ADR-weight gain, hypoglycemia 
• Inexpensive 
• Formulary 
• Efficacy/Evidence-Decreases microvascular 
• Monitoring 
– Renal function 
– Glyburide – active metabolite 
 
22 
Meglitinides 
• Repaglinide (Prandin), nateglinide (Starlix) 
• MoA-similar to SU 
• Decreases A1c  0.5-1.5% 
• Monitoring 
– Renal function 
• Concerns/Differences 
– Wt gain 
– Expense 
 
23 
Thiazolidindiones 
• Pioglitazone (Actos), rosiglitazone (Avandia) 
• Rosiglitazone-market status? 
• MoA-increased glucose utilization  
• Decreases A1c 0.5-1.5% 
• Diabetes Prevention 
• Monitoring 
– LFTs 
• Concerns/Differences 
– CV risk – rosiglitazone 
– Cancer risk – pioglitazone 
– Sodium/water retention – CHF, wt gain 
– Onset 
– Expense-Not on formulary 
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Alpha-glucosidase inhibitors 
• Acarbose (Precose), Miglitol (Glyset) 
• Mechanism 
– Decreased GI absorption 
• Efficacy/Evidence 
– Lowers A1c 0.5-1% 
– Diabetes prevention 
• Monitoring 
– LFTs 
• Concerns/Differences 
– Hypoglycemia corrections 
– Flatulence/diarrhea 
– Binding of other drugs 
– Expense-Not on formulary 
 
25 
Incretin Hormones and Glucose 
Homeostasis 
1. Endocr Rev. 1999;20:876–913.  3. Diabetes Care. 2003;26:2929–2940. 
2. Curr Diab Rep. 2003;2:365–372.  4. Diabetes Metab Res Rev. 2002;18:430–441. 
Ingestion of food 
Beta cells 
Alpha cells 
Release of gut 
hormones- 
Incretin 
Pancreas 
Glucose-dependent 
  Insulin from beta cells 
(GLP-1 and GIP) 
Glucose 
uptake by 
muscles 
Glucose 
production  
by liver 
Blood 
glucose 
Glucose 
dependent 
 Glucagon from 
alpha cells 
(GLP-1) 
GI tract 
Active 
GLP-1 & GIP 
DPP-4 
enzyme 
Inactive 
GIP 
Inactive 
GLP-1 
26 
Dipeptidyl Peptidase-IV (DPP-4) Inhibitors 
• Formulary-saxagliptin (Onglyza), linagliptin (Tradjenta) 
• Not on formulary-sitagliptin (Januvia),  alogliptin (Nesina) 
• MoA 
– Prolongs incretin hormone (GLP-1, GIP) levels 
– Increasing insulin synthesis and release  
– Decreasing glucagon secretion  
• A1c decreases 0.5- 0.8% 
• Monitoring-renal function (lower dose) 
• Concerns/Differences 
– Sitagliptin, saxagliptin-adjust for renal dysfunction 
– Linagliptin-no dosage adjustment in renal dysfunction 
– Pancreatitis 
– HF 
 
27 Image: www.crlonline.com 
Glucagon like peptide-1  
(GLP-1) agonists 
• Exenatide (Byetta, Bydureon), liraglutide (Victoza) 
• Mechanism 
– Hormone analog 
– Increases insulin secretion 
– Decreases glucagon secretion 
• A1C lowering  0.5%–2.0% 
• SQ injection  
• Concerns/Differences 
– Long acting – dosed once weekly 
– CrCl < 30 – do not use 
– Nausea/hypoglycemia 
– Pancreatitis/thyroid cancer 
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Newest Oral Agents 
Selective sodium-glucose transporter-2  
inhibitors (SGLT-2) 
• Canagliflozin, dapagliflozin 
• MoA 
– Inhibitors of SGLT2 
– Result in increased glucose excretion 
and lower plasma glucose 
• A1C lowering 0.8%–1.2% 
• ADR-hypotension, hyperkalemia, 
genital mycotic infections, UTIs, 
increased urination  
• Weight loss, no hypoglycemia  
• Expensive 
• CrCl > 45 ml/min 
 29 
Amylin analog—Pramlintide (Symlin)  
• MoA-synthetic analog of human amylin that causes:  
– Glucose-dependent inhibition of glucagon secretion  
– Reduced rate of gastric emptying  
– Increased satiety  
• Efficacy (indicated for patients receiving mealtime insulin)  
– A1C lowering of 0.5%–0.7%  
• Dose-different for Type 1 and Type 2 
• Adverse effects  
– Nausea, vomiting, hypoglycemia with insulin 
• Contraindications  
– Gastroparesis  
– Hypoglycemic unawareness  
30 
Comparison of Insulin Profiles 
31 
Drugs and Primary Effects 
Fasting Glucose 
• Metformin 
• Insulin 
detemir/glargine 
• NPH insulin 
Mixed Glycemic 
Effects 
• Sulfonylurea 
• Mixed insulin 
• SGLT-2 inhibitor 
• Liraglutide and 
weekly exenatide 
• TZDs 
Postprandial 
Glucose 
• Regular insulin 
• Insulin 
aspart/lispro/ 
glulisine 
• Alpha-glucosidase 
• Meglitinides 
• DPP-4 inhibitors 
• Twice daily 
exenatide 
• Pramlintide 
32 
33 
Management 
of Type 2 
Diabetes in 
Children and 
Adolescents 
34 UptoDate Online-Management of newly diagnosed Type 2 Diabetes Mellitus in 
children and adolsecents Pediatrics 2013; 131 (2):364 
Algorithm for Adding/Intensifying Insulin 
Garber AJ. Et al.  Endocrine Practice. 2013; 19: 327-336 35 
What is “Intensive Control” of Diabetes? 
More than glycemic control 
 Glycemic control  
 (A1C < 7%) 
• Every 3 months 
 Blood Pressure 
Management  
 (< 140/80) 
• Every visit 
 Lipid Management  
 (LDL <100, TG < 150, HDL 
> 50) 
• Yearly   
 Aspirin Therapy 
 Immunizations 
• Influenza – yearly 
• Pneumococcal – at 
diagnosis 
• Hep B 
 Monitor for complications 
- yearly 
 Education 
• Self management 
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Key Points 
• Glycemic targets & BG-lowering therapies must 
be individualized 
• Diet, exercise, & education: foundation of any 
T2DM therapy program 
• Unless contraindicated, metformin = optimal 1st-
line drug 
• Ultimately, many patients will require insulin 
therapy alone or in combination with other 
agents to maintain BG control 
• Treatment decisions should involve the patient  
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Contact Information 
 
Ext 494 
melanie.claborn@swosu.edu 
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Class HbA1c 
lowering 
Advantages Disadvantages F/NF 
Biguanide 1-2% •  Extensive experience 
• No hypoglycemia 
• Weight neutral 
• ?  CVD 
• Gastrointestinal 
• Lactic acidosis 
• B-12 deficiency 
• Contraindications 
F 
SUs / 
Meglitinides 
1-2% 
0.5-1.5% 
 
• Extensive experience 
•  Microvasc. risk 
• Hypoglycemia 
• Weight gain 
• Low durability 
• ? Ischemic 
preconditioning 
F/NF 
TZDs 0.5-1.5% • No hypoglycemia 
• Durability 
•  TGs,  HDL-C  
• ?  CVD (pio) 
 
• Weight gain 
• Edema / heart failure 
• Bone fractures 
• ?  MI (rosi) 
• ? Bladder ca (pio) 
 
NF 
a-GIs 0.5-1% 
 
• No hypoglycemia 
• Nonsystemic 
•  Post-prandial glucose 
• ?  CVD events 
• Gastrointestinal 
• Dosing frequency 
• Modest  A1c 
 
NF 
Diabetes Care, Diabetologia.2012  
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Class HbA1c 
lowering 
Advantages Disadvantages F/NF 
DPP-4 
inhibitors 
0.5- 0.8% 
 
• No hypoglycemia 
• Well tolerated 
• Modest  A1c   
• ? Pancreatitis 
• Urticaria 
F 
SGLT-2 
inhibitors 
0.8-1.2% 
 
• Weight neutral or loss 
• No hypoglycemia 
•Mycotic infections 
•Hyperkalemia, 
hypotension 
NF 
GLP-1 
receptor 
agonists 
0.5-2.0% • Weight loss 
• No hypoglycemia 
• ? Beta cell mass 
• ? CV protection 
• GI 
• ? Pancreatitis 
• Medullary ca 
• Injectable 
NF 
Amylin 
mimetics 
0.5%–0.7%  • Weight loss 
•  PPG 
• GI 
• Modest  A1c  
• Injectable 
• Hypo w/ insulin 
• Dosing frequency 
NF 
Bile acid 
sequestrants 
0.5%? • No hypoglycemia 
• Nonsystemic 
•  Post-prandial glucose 
•  CVD events 
• GI 
• Modest  A1c 
• Dosing frequency 
F 
41 
Adverse Effect Profiles 
42 
